Cargando…
Joint symptoms associated with anastrozole and letrozole in patients with breast cancer: a retrospective comparative study
BACKGROUND: Joint symptoms are a common side effect of aromatase inhibitors. However, it is not known if the risk of these symptoms varies between the members of this drug class. The aim of this study was to compare the frequency of joint symptoms associated with anastrozole and that associated with...
Autores principales: | Morimoto, Yoshihito, Sarumaru, Shuhei, Oshima, Yuko, Tsuruta, Chiho, Watanabe, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688801/ https://www.ncbi.nlm.nih.gov/pubmed/29177067 http://dx.doi.org/10.1186/s40780-017-0095-6 |
Ejemplares similares
-
A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015) -
Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
por: Aphinives, Potchavit, et al.
Publicado: (2014) -
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011) -
Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014) -
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)